RTSL (Rapid Therapeutic Science Laboratories) ROC %: -7.85% (As of Jun. 2023)


What is Rapid Therapeutic Science Laboratories ROC %?

Rapid Therapeutic Science Laboratories RTSL ROC % is -7.85% as of Jun. 2023.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Rapid Therapeutic Science Laboratories's annualized return on capital (ROC %) for the quarter that ended in Jun. 2023 was -7.85%.

As of today (2026-06-24), Rapid Therapeutic Science Laboratories's WACC % is 0.00%. Rapid Therapeutic Science Laboratories's ROC % is 0.00% (calculated using TTM income statement data). Rapid Therapeutic Science Laboratories earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Rapid Therapeutic Science Laboratories  (OTCPK:RTSL) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Rapid Therapeutic Science Laboratories's WACC % is 0.00%. Rapid Therapeutic Science Laboratories's ROC % is 0.00% (calculated using TTM income statement data). Rapid Therapeutic Science Laboratories earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Rapid Therapeutic Science Laboratories ROC % Related Terms

Rapid Therapeutic Science Laboratories ROC % Historical Data

* Premium members only.

The historical data trend for Rapid Therapeutic Science Laboratories's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Therapeutic Science Laboratories ROC % Chart

Rapid Therapeutic Science Laboratories Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -44.77 -24.46 -43.67 -78.20 -24.54

Rapid Therapeutic Science Laboratories Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.24 -24.57 1.81 -6.92 -7.85

Rapid Therapeutic Science Laboratories ROC % Calculation

Rapid Therapeutic Science Laboratories's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-1.263 * ( 1 - 0% )/( (4.323 + 5.972)/ 2 )
=-1.263/5.1475
=-24.54 %

where

Invested Capital(A: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.2 - 0.511 - ( 0.192 - max(0, 3.053 - 0.419+0.192))
=4.323

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.255 - 1.016 - ( 0 - max(0, 4.966 - 0.233+0))
=5.972

Rapid Therapeutic Science Laboratories's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2023 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-0.416 * ( 1 - 0% )/( (5.362 + 5.238)/ 2 )
=-0.416/5.3
=-7.85 %

where

Invested Capital(Q: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.034 - 0.884 - ( 0.018 - max(0, 4.463 - 0.251+0.018))
=5.362

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.074 - 0.944 - ( 0.002 - max(0, 4.426 - 0.318+0.002))
=5.238

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -7.85% mean?
Rapid Therapeutic Science Laboratories (RTSL) has a ROC % of -7.85% as of Jun. 2023. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Rapid Therapeutic Science Laboratories and its competitors.
Is Rapid Therapeutic Science Laboratories' ROC % too high?
Rapid Therapeutic Science Laboratories' current ROC % is -7.85%.
How does Rapid Therapeutic Science Laboratories' ROC % compare to VRAYQ and NNMX?
Rapid Therapeutic Science Laboratories' ROC % of -7.85% can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Diversified Financial Services company?
A good ROC % depends on the Diversified Financial Services industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Rapid Therapeutic Science Laboratories and its competitors. Rapid Therapeutic Science Laboratories's current ROC % is -7.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Therapeutic Science Laboratories stock overvalued right now?
Rapid Therapeutic Science Laboratories (RTSL) has a current ROC % of -7.85%. The current ROC % is -7.85%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Rapid Therapeutic Science Laboratories (RTSL), the current ROC % is -7.85% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapid Therapeutic Science Laboratories Business Description

Address 558 County Road 472, De Leon, TX, USA, 76444
Rapid Therapeutic Science Laboratories Inc currently has no operations and operates as a blank check company.